This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 SpecialtyPharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S.
Asembia’s SpecialtyPharmacy Summit 2022. Asembia's SpecialtyPharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialtypharmacy. Plus, Doug Long from IQVIA and I will again lead the Featured Session, titled The SpecialtyPharmacy Industry Update and Outlook.
27, 2023) – Amber SpecialtyPharmacy announces today that Craig Holtgrave has been named senior vice president of business innovation. Holtgrave joins Amber SpecialtyPharmacy with more than 18 years of sales experience in the health care industry, with a strong focus in pharmaceuticalmanufacturing and pharmacy operations.
This includes a highly coordinated team and effort from multiple specialists, their care staff, the pharmaceuticalmanufacturer, the rare disease specialtypharmacy provider, and their patient support team. Almost 1 in 10 Americans are affected by a rare disease.
Before any anticipated specialty drug launch, a pharmaceuticalmanufacturer conducts an extensive market access evaluation to determine the best distribution model for their specialty drug. In general, there are three distinct drug distribution models to consider for a specialty drug launch: open, limited, and exclusive.
billion annually because of these restrictions, as drug companies limit 340B discounts on medications purchased through contract pharmacies. billion in 340B savings is at risk, due to increasing limitations imposed by pharmaceuticalmanufacturers which could further strain the healthcare safety net and patient care services.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
What’s more, according to Acentrus Specialty , a specialtypharmacy consulting firm, 8 out of 10 new drugs approved by the FDA in 2020 were specialty drugs. In short, specialty drugs constitute the fastest-growing and largest part of the prescription-drug market.
reviews the evolving specialtypharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. The notable new material in this 2023-24 edition includes: New data about commercial pricing and reimbursement for provider-administered biosimilars appears in Section 3.2.2.
Weve updated all market and industry data with the most current insights, including our annual analyses of the largest pharmacies, specialtypharmacies, and PBMs. WHATS GOING ON Twice a year, the DCI team researches and writes two comprehensive, fact-based, and nonpartisan reports on drug channel economics.
We can also see from this excerpt that at the scale of large PBMs, formulary strategies are also a piece of negotiating leverage to obtain rebates and fees from pharmaceuticalmanufacturers. However, once negotiations are completed and rebate contracted executed, rebates can be cut off punitively by pharmaceuticalmanufacturers.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content